Comparative Pharmacology
Head-to-head clinical analysis: FENOGLIDE versus OMACOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOGLIDE versus OMACOR.
FENOGLIDE vs OMACOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
Omega-3-acid ethyl esters (EPA and DHA) reduce hepatic triglyceride synthesis by inhibiting acyl-CoA:1,2-diacylglycerol acyltransferase and increasing beta-oxidation. They also decrease very-low-density lipoprotein (VLDL) secretion and enhance triglyceride clearance from circulating VLDL particles.
160 mg orally once daily, taken with or without food.
4 g orally once daily or 2 g orally twice daily, taken with meals. Each capsule contains 1 g of omega-3-acid ethyl esters (approximately 465 mg eicosapentaenoic acid and 375 mg docosahexaenoic acid).
None Documented
None Documented
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
Terminal elimination half-life: ~55–75 hours for EPA and DHA (beta-phase). Clinical context: steady-state achieved after 4–8 weeks; half-life supports once-daily dosing.
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
Primarily fecal as unchanged drug and metabolites; <5% renal. Biliary excretion accounts for ~90% of elimination via feces, with minimal urinary excretion (0.5–2%).
Category C
Category C
Antilipemic
Antilipemic